Chembio Diagnostics Inc (CEMI)

NASDAQ
1.030
-0.060(-5.50%)
After Hours
1.040
+0.010(+0.971%)
- Real-time Data
  • Volume:
    540,359
  • Bid/Ask:
    1.030/1.040
  • Day's Range:
    1.030 - 1.110

CEMI Overview

Prev. Close
1.09
Day's Range
1.03-1.11
Revenue
37.47M
Open
1.09
52 wk Range
1.03-8.55
EPS
-1.26
Volume
540,359
Market Cap
30.95M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,363,158
P/E Ratio
-
Beta
1.67
1-Year Change
-82.57%
Shares Outstanding
30,045,141
Next Earnings Date
Mar 10, 2022
What is your sentiment on Chembio Diagnostics Inc?
or
Market is currently closed. Voting is open during market hours.

Chembio Diagnostics Inc Company Profile

Chembio Diagnostics, Inc. develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Its DPP technology offers range of market applications beyond infectious disease. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in approximately 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, pregnancy and fertility, and drugs of abuse. It targets rapid diagnostic test solutions for infectious diseases, including respiratory diseases, sexually transmitted diseases, gastroenterology and insect-vector diseases. The Company sells its products under the DPP, STAT PAK, SURE CHECK and STAT-VIEW trademarks.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Chembio Diagnostics Inc - on December 21, FDA Notified Co That It Was Declining to Review Co's Application for Eua for Dpp Respiratory Antigen Panel. Chembio -fda Notice Said Co Will Need to Collect Influenza a & Influenza B Samples, Submit New Eua Application for Dpp Respiratory Antigen Panel.
    1
    • Any news?
      0
      • Chembio Diagnostics (CEMI) gains 9.5% premarket after receiving South Africa Health Products Regulatory Authority ((SAHPRA)) approval for the DPP SARS-CoV-2 Antigen test,...
        0
        • up up
          0
          • HAUPPAUGE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all of the $28.3 million order. Chembio's delivery of tests covered by the purchase order, however, continues to be negatively affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.
            0
            • But I expect a rapid rise in the near future... I expect to sign an agreement to manufacture Covid devices
              0
              • bad report
                0
                • 2 Major orders in this last Quarter Why is this stock not going up? what am i missing thats not in the news?
                  0
                  • 2.59 good to buy in my opinion
                    0
                    • hm hm hm
                      0
                      • 👍👍👍👍👍
                        0
                        • I think there is a big explosion coming soon
                          0
                          • Break coming around 1130
                            0
                            • 🚀
                              0
                              • Selling at 7.5 $
                                0
                                • Chembio Diagnostics Inc (NASDAQ: CEMI) has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test.  Product inventory is on-hand and immediately available for shipment to Chembio customers ...
                                  0
                                  • Vol is off the hook
                                    0
                                    • otw to usd4
                                      0
                                      • Is just me or this taking the exact same path as sprt.
                                        0
                                        • So how much do u expect
                                          0
                                        • 15 to 20
                                          0
                                      • Hum could be a Interesting day
                                        0
                                        • The world wants what they have. A test that can tell differnce between covid and Influenza.
                                          0
                                          • my target sell 3.5 vary soon
                                            0
                                            • loding
                                              0
                                              • invest guys this is cheap
                                                0
                                                • Shorts wont let this one get lose again.
                                                  0
                                                  • keep giving false hope to people, i know you are getting paid under the table from Chembio to keep pumping wrong info. People wont fall for the same traps over and over again...
                                                    0
                                                  • No im not getting paid sundhine
                                                    0
                                                  • World TravelerI wish Im paid lol last loaded at 2.50
                                                    0
                                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.